AC Immune AG reports results for the quarter ended September 30 - Earnings Summary

• AC Immune AG reported a quarterly adjusted loss of 13 rappen​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -16 rappen. The mean expectation of four analysts for the quarter was for a loss of 16 rappen per share. Wall Street expected results to range from -20 rappen to -13 rappen per share.

• Revenue rose 245.5% to CHF3.24 million from a year ago; analysts expected CHF202.55 thousand.

• AC Immune AG's reported EPS for the quarter was a loss of 13 rappen​.

• The company reported a quarterly loss of CHF8.75 million.

• AC Immune AG shares had fallen by 20.2% this quarter and lost 33.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for AC Immune AG is $9.47, about 77.9% above its last closing price of $2.09

This summary was machine generated from LSEG data November 4 at 01:45 p.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)